Niihara Yutaka's Form 4 filing
Emmaus Life Sciences, Inc. (EMMA) · filed Sep 27, 2021
- Accession no.
- 0001209191-21-057831
- Filed
- Sep 27, 2021
- Trade date
- Sep 23-24, 2021
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market purchases total $4.24K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Niihara YutakaCIK 0001517691 | Director, Officer (Chairman and CEO), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 23, 2021 | Common stock, $0.001 par value | PPurchaseAcquired | +1,500 | $1.69 | +$2,535 | 10,880,147 | Direct | |
| Sep 24, 2021 | Common stock, $0.001 par value | PPurchaseAcquired | +1,000 | $1.70 | +$1,700 | 10,881,147 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.